The research-grade biosimilar is an investigational humanised IgG4 monoclonal antibody that specifically inhibits CCR5. CCR5 is a chemokine receptor that is expressed on the surface of a broad range of cells including T-cells, B-cells, and macrophages, and plays an important role in immune responses. Human Immunodeficiency Virus 1 (HIV-1) uses CCR5 as a co-receptor to enter and infect immunologic cells. The antibody binds to the hydrophilic extracellular domains of the CCR5 and competitively inhibits the CCR5-mediated HIV-1 entry into the host cells. The antibody does not target viruses using CXCR4 as a receptor to enter host cells. The original drug was granted Fast Track Designation by the US FDA to treat HIV infected patients in combination with HAART, and for metastatic triple-negative breast cancer. Currently, the drug is in early clinical trials to treat COVID-19 disease.
In PBS, pH 7.5